Hot or Not, Stock Market Edition: 03/13/2026

Happy Friday. Here are the stock stories we're following today:

• Hot: Pharmaceutical player Amneal Pharmaceuticals (AMRX) is catching fire; Medical equipment player Envista (NVST) is gaining momentum.
• Not: Lean times for Conagra Brands (CAG); property & casualty insurer Kinsale Capital Group (KNSL) is losing steam

P.S. Speaking of hot, check out this video featuring 6 hidden gems you’ve never heard of.

A note from our sponsors...

🔥 HOT: Medical equipment player Envista (NVST) is catching fresh attention after a recent pullback of 12% in the past month. What's behind the move? 1) Overall, the stock has surged 20% over the past three months despite that drop in the past month; some believe this dip is temporary. Recent headlines highlight this as a potential "buy the bottom" opportunity after witnessing a hammer chart pattern — indicating support found after losing ground lately. 2) Multiple outlets flagged NVST as one of the best value stocks to buy in the last week or so, signaling renewed interest in its valuation after the pullback. (Stay up to date on the latest ratings changes here.) 3) The stock holds a Zen Rating of A and ranks in the top 3% of equities we track based on a 115-factor review. It has a few standout Component Grades worth mentioning: A Grades for Growth and Safety, and a B Grade for Sentiment and Value. The verdict? This medical device name appears positioned for a rebound as value-focused investors circle after the recent dip.

🥶 NOT:  Property & casualty insurer Kinsale Capital Group (KNSL) is losing steam. What's going on? 1) Analyst commentary has turned cautious, with the fair value estimate recently trimmed from $433.40 to $422.40, reflecting concerns about slower premium growth even as profitability holds up. 2) The stock is down sharply across all timeframes — trading at $360.64, it's fallen 4.5% from its 10-day average, 4.9% from its 20-day average, and a hefty 15.4% below its 200-day average of $426.13. 3) Even if you can’t understand that technical stuff, this is pretty simple to understand: It has a Zen Rating of D or Sell, ranking it near the bottom of the 4600+ stocks we track. Looking at the Component Grades, it struggles with a D Grade for Momentum and Sentiment, signaling technical weakness and fading investor confidence. The verdict? Despite strong margins and structural strengths, the stock's deteriorating momentum and negative sentiment make this a name to avoid until growth re-accelerates.

🔥 HOT: Pharmaceutical player Amneal Pharmaceuticals (AMRX) is catching fire. Not only is it one of our Zen Investor Editor-in-Chief’s favorite pharma stocks for 2026, but there are a few other points of interest: 1) Despite short-term weakness — shares are down about 13% in the past month — the longer trend looks solid, with the stock up 43% in the past year. 2) The stock holds a Zen Rating of A and actually ranks in the 99.8th percentile of the 4600+ stocks we track — no small feat. Looking at the Component Grades to reveal particular strengths, it earns an A Grade for Growth and B Grades for Momentum, Sentiment, and Value. The verdict? Amneal is showing institutional-quality fundamentals with room to run, and the recent pullback could be a buy-the-dip opportunity for investors willing to ride out near-term volatility. (See more of our Zen Investor stock picks here.)

🥶 NOT: Packaged foods maker Conagra Brands (CAG) is hitting a rough patch despite recent expansion news. While the company announced a $220 million expansion of its Arkansas chicken production facility to boost capacity for protein-focused frozen meals (Hungry-Man, Banquet, Healthy Choice), investor sentiment toward packaged food names has weakened following cautious guidance from competitors. The stock fell nearly 6% in one session after industry peer Campbell's Co reported disappointing quarterly results and slashed its full-year profit outlook — dragging down packaged food peers including CAG. The stock is down roughly 10% from its recent highs, and down 36% over the past year. The stock holds a Zen Rating of C, placing it in Hold territory. It struggles with a D Grade for Growth and Momentum, though it maintains decent Safety (B Grade) and Value (C Grade) scores. The bottom line? Hold. The fundamentals suggest waiting for clearer signs of recovery.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.